PN-235 is a synthetic peptide commercialized by Protagonist Therapeutics, with a leading Phase II program in Plaque Psoriasis (Psoriasis Vulgaris). According to Globaldata, it is involved in 7 clinical trials, of which 3 were completed, 2 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of PN-235’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for PN-235 is expected to reach an annual total of $56 mn by 2037 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

PN-235 Overview

PN-235 is under development for the treatment of inflammatory bowel disease and plaque psoriasis. It is administered by the oral route. The drug candidate acts by targeting IL-23 receptor and being developed based on the peptide technology platform.

Protagonist Therapeutics Overview

Protagonist Therapeutics (Protagonist) is a clinical-stage biopharmaceutical company that discovers and develops orally stable peptides as targeted therapies. The company through its proprietary technology platform develops structurally novel oral or injectable peptides for protein-protein interaction targets. Protagonist’s peptides specifically target biological pathways that are also targeted by currently marketed injectable antibody drugs. Protagonist’ product candidates are intended for the treatment of inflammatory bowel disease and other gastrointestinal diseases and hematological disorders. The company has its operations in the US and Australia. Protagonist is headquartered in Milpitas, California, the US.

The company reported revenues of (US Dollars) US$27.4 million for the fiscal year ended December 2021 (FY2021), a decrease of 4.4% over FY2020. The operating loss of the company was US$125.8 million in FY2021, compared to an operating loss of US$65.1 million in FY2020. The net loss of the company was US$125.6 million in FY2021, compared to a net loss of US$66.2 million in FY2020.

For a complete picture of PN-235’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.